Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has a beta value of 1.39 and has seen 150,000,000 shares traded in the last trading session. The company, currently valued at $4.74 Billion, closed the last trade at $29.98 per share which meant it lost -$1.2 on the day or -4.06% during that session. The INO stock price is -12.71% off its 52-week high price of $33.79 and 93.6% above the 52-week low of $1.92. If we look at the company’s 10-day average daily trading volume, we find that it stood at 81.01 Million shares traded. The 3-month trading volume is 37.11 Million shares.

The consensus among analysts is that Inovio Pharmaceuticals, Inc. (INO) is an Overweight stock at the moment, with a recommendation rating of 2.2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 4 out of 8 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.17.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) trade information

Despite being -4.06% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Jun 26 when the INO stock price touched $33.79- or saw a rise of 11.28%. Year-to-date, Inovio Pharmaceuticals, Inc. shares have moved 808.48%, while the 5-day performance has seen it change 110.09%. Over the past 30 days, the shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have changed 107.33%. Short interest in the company has seen 25.78 Million shares shorted with days to cover at 0.69.

Wall Street analysts have a consensus price target for the stock at $21.88, which means that the shares’ value could jump -27.02% from current levels. The projected low price target is $8 while the price target rests at a high of $45. In that case, then, we find that the current price level is +50.1% off the targeted high while a plunge would see the stock lose -73.32% from current levels.

Inovio Pharmaceuticals, Inc. (INO) estimates and forecasts

Figures show that Inovio Pharmaceuticals, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +744.51% over the past 6 months, with this year growth rate of -36.21%, compared to 9.2% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 43.3% and 36% for the next quarter. Revenue growth from the last financial year stood is estimated to be +921.6%.

8 analysts offering their estimates for the company have set an average revenue estimate of $2.6 Million for the current quarter. 8 have an estimated revenue figure of $3.49 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $136Million and $866Million respectively for this quarter and the next, and analysts expect sales will grow by 1811.8% for the current quarter and 303% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -14.6% over the past 5 years. Earnings growth for 2020 is a modest -15.4% while over the next 5 years, the company’s earnings are expected to increase by 0%.